tiprankstipranks
Crispr Therapeutics AG (GB:0VRQ)
LSE:0VRQ
UK Market
0VRQ
Crispr Therapeutics AG
RESEARCH TOOLSreports

Crispr Therapeutics AG (0VRQ) Share Forecast & Price Target

8 Followers
See the Price Targets and Ratings of:

0VRQ Analyst Ratings

Moderate Buy
13Ratings
Moderate Buy
8 Buy
5 Hold
0 Sell
Based on 13 analysts giving stock ratings to
Crispr
Therapeutics AG
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

0VRQ Stock 12 Month Forecast

Average Price Target

$74.33
▲(57.39% Upside)
Based on 13 Wall Street analysts offering 12 month price targets for Crispr Therapeutics AG in the last 3 months. The average price target is $74.33 with a high forecast of $110.00 and a low forecast of $45.00. The average price target represents a 57.39% change from the last price of $47.23.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"44":"$44","111":"$111","60.75":"$60.8","77.5":"$77.5","94.25":"$94.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":110,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$110.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":74.33333333333333,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$74.33</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":45,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$45.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[44,60.75,77.5,94.25,111],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,47.8,52.58461538461538,57.36923076923077,62.153846153846146,66.93846153846154,71.72307692307692,76.50769230769231,81.29230769230769,86.07692307692307,90.86153846153846,95.64615384615385,100.43076923076923,105.21538461538461,{"y":110,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,47.8,49.84102564102564,51.88205128205128,53.92307692307692,55.96410256410256,58.0051282051282,60.04615384615384,62.08717948717948,64.12820512820512,66.16923076923077,68.2102564102564,70.25128205128205,72.29230769230769,{"y":74.33333333333333,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,47.8,47.58461538461538,47.36923076923077,47.15384615384615,46.93846153846154,46.723076923076924,46.50769230769231,46.29230769230769,46.07692307692307,45.86153846153846,45.646153846153844,45.43076923076923,45.215384615384615,{"y":45,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":56.145,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":51.734,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":64.931,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":64,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":53.099,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":52.772,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":51.37,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":60.11,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":48.941,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":51.73,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":55.12,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":55.53,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":47.8,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$110.00Average Price Target$74.33Lowest Price Target$45.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
William Blair Analyst forecast on GB:0VRQ
Sami Corwin
William Blair
William Blair
―
Buy
―
Reiterated
08/28/26
Crispr Therapeutics AG (CRSP) Gets a Buy from William Blair
Morgan Stanley Analyst forecast on GB:0VRQ
Maxwell Skor
Morgan Stanley
Morgan Stanley
$60
Hold
27.04%
Upside
Reiterated
08/28/26
Crispr Therapeutics durability data 'encouraging,' says Morgan StanleyCrispr Therapeutics durability data 'encouraging,' says Morgan Stanley
Goldman Sachs Analyst forecast on GB:0VRQ
Salveen Richter
Goldman Sachs
Goldman Sachs
$48→$55
Hold
16.45%
Upside
Assigned
08/10/26
Goldman Sachs Keeps Their Hold Rating on Crispr Therapeutics AG (CRSP)
Wells Fargo Analyst forecast on GB:0VRQ
Yanan Zhu
Wells Fargo
Wells Fargo
$75
Hold
58.80%
Upside
Reiterated
08/05/26
Crispr Therapeutics AG (CRSP) Receives a Hold from Wells Fargo
H.C. Wainwright Analyst forecast on GB:0VRQ
Mitchell Kapoor
H.C. Wainwright
H.C. Wainwright
$80
Buy
69.38%
Upside
Reiterated
08/05/26
CRISPR Therapeutics: Buy Rating Reiterated, $80 Price Target Maintained Ahead of Key HORIZON Catalyst
Bank of America Securities Analyst forecast on GB:0VRQ
Alec Stranahan
Bank of America Securities
Bank of America Securities
$83→$82
Buy
73.62%
Upside
Reiterated
08/05/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
Needham Analyst forecast on GB:0VRQ
Gil Blum
Needham
Needham
$82
Buy
73.62%
Upside
Reiterated
08/04/26
Crispr Therapeutics: Strong Casgevy Uptake, Expanding Pipeline and Cash Runway Support Unchanged $82 Price Target and Buy Rating
Piper Sandler Analyst forecast on GB:0VRQ
Edward Tenthoff
Piper Sandler
Piper Sandler
$110
Buy
132.90%
Upside
Reiterated
08/04/26
Piper Sandler Reaffirms Their Buy Rating on Crispr Therapeutics AG (CRSP)
TD Cowen Analyst forecast on GB:0VRQ
Tyler Van Buren
TD Cowen
TD Cowen
$45
Hold
-4.72%
Downside
Reiterated
08/03/26
Analysts Offer Insights on Healthcare Companies: Crispr Therapeutics AG (NASDAQ: CRSP), Supernus Pharmaceuticals (NASDAQ: SUPN) and Krystal Biotech (NASDAQ: KRYS)
Citi Analyst forecast on GB:0VRQ
Yigal Nochomovitz
Citi
Citi
$82→$88
Buy
86.32%
Upside
Reiterated
08/03/26
Casgevy Momentum and Pipeline Catalysts Drive Yigal Nochomovitz to Maintain Buy Rating and Raise Price Target to $88
RBC Capital Analyst forecast on GB:0VRQ
Luca Issi
RBC Capital
RBC Capital
$50
Hold
5.86%
Upside
Reiterated
08/03/26
RBC Capital Keeps Their Hold Rating on Crispr Therapeutics AG (CRSP)
Citizens JMP Analyst forecast on GB:0VRQ
Silvan Turkcan
Citizens JMP
Citizens JMP
$80
Buy
69.38%
Upside
Reiterated
07/22/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Crispr Therapeutics AG (NASDAQ: CRSP) and GlaxoSmithKline (LSE: GB:GSK)
Mizuho Securities Analyst forecast on GB:0VRQ
Unknown Analyst
Mizuho Securities
Not Ranked
Mizuho Securities
$85
Buy
79.97%
Upside
Reiterated
06/10/26
Crispr Therapeutics AG (CRSP) Gets a Buy from Mizuho Securities
Bernstein Analyst forecast on GB:0VRQ
William Pickering
Bernstein
Bernstein
$50→$56
Hold
18.57%
Upside
Assigned
05/13/26
Crispr Therapeutics price target raised to $56 from $50 at BernsteinCrispr Therapeutics price target raised to $56 from $50 at Bernstein
Evercore ISI Analyst forecast on GB:0VRQ
Jonathan Miller
Evercore ISI
Evercore ISI
$74→$76
Buy
60.91%
Upside
Reiterated
05/11/26
Crispr Therapeutics price target raised to $76 from $74 at Evercore ISICrispr Therapeutics price target raised to $76 from $74 at Evercore ISI
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
William Blair Analyst forecast on GB:0VRQ
Sami Corwin
William Blair
William Blair
―
Buy
―
Reiterated
08/28/26
Crispr Therapeutics AG (CRSP) Gets a Buy from William Blair
Morgan Stanley Analyst forecast on GB:0VRQ
Maxwell Skor
Morgan Stanley
Morgan Stanley
$60
Hold
27.04%
Upside
Reiterated
08/28/26
Crispr Therapeutics durability data 'encouraging,' says Morgan StanleyCrispr Therapeutics durability data 'encouraging,' says Morgan Stanley
Goldman Sachs Analyst forecast on GB:0VRQ
Salveen Richter
Goldman Sachs
Goldman Sachs
$48→$55
Hold
16.45%
Upside
Assigned
08/10/26
Goldman Sachs Keeps Their Hold Rating on Crispr Therapeutics AG (CRSP)
Wells Fargo Analyst forecast on GB:0VRQ
Yanan Zhu
Wells Fargo
Wells Fargo
$75
Hold
58.80%
Upside
Reiterated
08/05/26
Crispr Therapeutics AG (CRSP) Receives a Hold from Wells Fargo
H.C. Wainwright Analyst forecast on GB:0VRQ
Mitchell Kapoor
H.C. Wainwright
H.C. Wainwright
$80
Buy
69.38%
Upside
Reiterated
08/05/26
CRISPR Therapeutics: Buy Rating Reiterated, $80 Price Target Maintained Ahead of Key HORIZON Catalyst
Bank of America Securities Analyst forecast on GB:0VRQ
Alec Stranahan
Bank of America Securities
Bank of America Securities
$83→$82
Buy
73.62%
Upside
Reiterated
08/05/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
Needham Analyst forecast on GB:0VRQ
Gil Blum
Needham
Needham
$82
Buy
73.62%
Upside
Reiterated
08/04/26
Crispr Therapeutics: Strong Casgevy Uptake, Expanding Pipeline and Cash Runway Support Unchanged $82 Price Target and Buy Rating
Piper Sandler Analyst forecast on GB:0VRQ
Edward Tenthoff
Piper Sandler
Piper Sandler
$110
Buy
132.90%
Upside
Reiterated
08/04/26
Piper Sandler Reaffirms Their Buy Rating on Crispr Therapeutics AG (CRSP)
TD Cowen Analyst forecast on GB:0VRQ
Tyler Van Buren
TD Cowen
TD Cowen
$45
Hold
-4.72%
Downside
Reiterated
08/03/26
Analysts Offer Insights on Healthcare Companies: Crispr Therapeutics AG (NASDAQ: CRSP), Supernus Pharmaceuticals (NASDAQ: SUPN) and Krystal Biotech (NASDAQ: KRYS)
Citi Analyst forecast on GB:0VRQ
Yigal Nochomovitz
Citi
Citi
$82→$88
Buy
86.32%
Upside
Reiterated
08/03/26
Casgevy Momentum and Pipeline Catalysts Drive Yigal Nochomovitz to Maintain Buy Rating and Raise Price Target to $88
RBC Capital Analyst forecast on GB:0VRQ
Luca Issi
RBC Capital
RBC Capital
$50
Hold
5.86%
Upside
Reiterated
08/03/26
RBC Capital Keeps Their Hold Rating on Crispr Therapeutics AG (CRSP)
Citizens JMP Analyst forecast on GB:0VRQ
Silvan Turkcan
Citizens JMP
Citizens JMP
$80
Buy
69.38%
Upside
Reiterated
07/22/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Crispr Therapeutics AG (NASDAQ: CRSP) and GlaxoSmithKline (LSE: GB:GSK)
Mizuho Securities Analyst forecast on GB:0VRQ
Unknown Analyst
Mizuho Securities
Not Ranked
Mizuho Securities
$85
Buy
79.97%
Upside
Reiterated
06/10/26
Crispr Therapeutics AG (CRSP) Gets a Buy from Mizuho Securities
Bernstein Analyst forecast on GB:0VRQ
William Pickering
Bernstein
Bernstein
$50→$56
Hold
18.57%
Upside
Assigned
05/13/26
Crispr Therapeutics price target raised to $56 from $50 at BernsteinCrispr Therapeutics price target raised to $56 from $50 at Bernstein
Evercore ISI Analyst forecast on GB:0VRQ
Jonathan Miller
Evercore ISI
Evercore ISI
$74→$76
Buy
60.91%
Upside
Reiterated
05/11/26
Crispr Therapeutics price target raised to $76 from $74 at Evercore ISICrispr Therapeutics price target raised to $76 from $74 at Evercore ISI
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
ODTXOdyssey Therapeutics, Inc.
AVBPArriVent BioPharma, Inc.
BTSGBrightSpring Health Services, Inc.
GPCRStructure Therapeutics, Inc. Sponsored ADR
AMLXAmylyx Pharmaceuticals Inc
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Crispr Therapeutics AG

3 Months
Mani ForooharLeerink Partners
Success Rate
13/22 ratings generated profit
59%
Average Return
+7.56%
Copying Mani Foroohar's trades and holding each position for 3 Months would result in 59.09% of your transactions generating a profit, with an average return of +7.56% per trade.
1 Year
Alec StranahanBank of America Securities
Success Rate
15/18 ratings generated profit
83%
Average Return
+15.97%
Copying Alec Stranahan's trades and holding each position for 1 Year would result in 83.33% of your transactions generating a profit, with an average return of +15.97% per trade.
2 Years
Sami CorwinWilliam Blair
Success Rate
15/17 ratings generated profit
88%
Average Return
+15.18%
Copying Sami Corwin's trades and holding each position for 2 Years would result in 88.24% of your transactions generating a profit, with an average return of +15.18% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

0VRQ Analyst Recommendation Trends

Rating
Apr 26
May 26
Jun 26
Jul 26
Aug 26
Strong Buy
9
9
9
9
9
Buy
6
6
6
7
5
Hold
3
5
5
6
8
Sell
1
0
0
0
0
Strong Sell
0
0
0
0
0
total
19
20
20
22
22
In the current month, 0VRQ has received 14 Buy Ratings, 8 Hold Ratings, and 0 Sell Ratings. 0VRQ average Analyst price target in the past 3 months is 74.33.
Each month's total comprises the sum of three months' worth of ratings.

0VRQ Financial Forecast

0VRQ Earnings Forecast

Next quarter’s earnings estimate for 0VRQ is -$1.05 with a range of -$1.50 to -$0.46. The previous quarter’s EPS was -$0.94. 0VRQ beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year 0VRQ has Performed in-line its overall industry.
Next quarter’s earnings estimate for 0VRQ is -$1.05 with a range of -$1.50 to -$0.46. The previous quarter’s EPS was -$0.94. 0VRQ beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year 0VRQ has Performed in-line its overall industry.

0VRQ Sales Forecast

Next quarter’s sales forecast for 0VRQ is $14.84M with a range of $0.00 to $77.25M. The previous quarter’s sales results were $10.18M. 0VRQ beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year 0VRQ has Performed in-line its overall industry.
Next quarter’s sales forecast for 0VRQ is $14.84M with a range of $0.00 to $77.25M. The previous quarter’s sales results were $10.18M. 0VRQ beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year 0VRQ has Performed in-line its overall industry.

0VRQ Stock Forecast FAQ

What is GB:0VRQ’s average 12-month price target, according to analysts?
Based on analyst ratings, Crispr Therapeutics AG’s 12-month average price target is 74.33.
    What is GB:0VRQ’s upside potential, based on the analysts’ average price target?
    Crispr Therapeutics AG has 57.39% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is Crispr Therapeutics AG a Buy, Sell or Hold?
          Crispr Therapeutics AG has a consensus rating of Moderate Buy, which is based on 8 buy ratings, 5 hold ratings and 0 sell ratings.
            What is Crispr Therapeutics AG’s share price target?
            The average share price target for Crispr Therapeutics AG is 74.33. This is based on 13 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is $110.00 ,and the lowest forecast is $45.00. The average share price target represents 57.39% Increase from the current price of $47.23.
              What do analysts say about Crispr Therapeutics AG?
              Crispr Therapeutics AG’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 13 Wall Streets Analysts.
                How can I buy shares of Crispr Therapeutics AG?
                To buy shares of GB:0VRQ, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.